T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
World game at war: why some European nations have threatened a World Cup boycott 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
BOSTON, May 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2018.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 6639039. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 7:30 p.m. ET on May 8, 2018 through May 15, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 6639039.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company’s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Media
Krystle Gibbs
Ten Bridge Communications
[email protected]
508-479-6358
Investors
John Woolford
Westwicke Partners
[email protected]
443-213-0506
